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ORIGINAL RESEARCH COMMUNICATION
Uncoupling Protein-2 Mediates DPP-4 Inhibitor-Induced
Restoration of Endothelial Function in Hypertension
Through Reducing Oxidative Stress
Limei Liu,1–3 Jian Liu,2,3 Xiao Yu Tian,2,3 Wing Tak Wong,2,3 Chi Wai Lau,2,3 Aimin Xu,4,5
Gang Xu,6 Chi Fai Ng,7 Xiaoqiang Yao,2,3 Yuansheng Gao,1 and Yu Huang2,3
Abstract
Aims: Although uncoupling protein 2 (UCP2) negatively regulates intracellular reactive oxygen species (ROS)
production and protects vascular function, its participation in vascular benefits of drugs used to treat cardio-
metabolic diseases is largely unknown. This study investigated whether UCP2 and associated oxidative stress
reduction contribute to the improvement of endothelial function by a dipeptidyl peptidase-4 inhibitor, si-
tagliptin, in hypertension. Results: Pharmacological inhibition of cyclooxygenase-2 (COX-2) but not COX-1
prevented endothelial dysfunction, and ROS scavengers reduced COX-2 mRNA and protein expression in
spontaneously hypertensive rats (SHR) renal arteries. Angiotensin II (Ang II) evoked endothelium-dependent
contractions (EDCs) in C57BL/6 and UCP2 knockout (UCP2KO) mouse aortae. Chronic sitagliptin adminis-
tration attenuated EDCs in SHR arteries and Ang II-infused C57BL/6 mouse aortae and eliminated ROS
overproduction in SHR arteries, which were reversed by glucagon-like peptide 1 receptor (GLP-1R) antagonist
exendin 9-39, AMP-activated protein kinase (AMPK)a inhibitor compound C, and UCP2 inhibitor genipin. By
contrast, sitagliptin unaffected EDCs in Ang II-infused UCP2KO mice. Sitagliptin increased AMPKa phos-
phorylation, upregulated UCP2, and downregulated COX-2 expression in arteries from SHR and Ang II-infused
C57BL/6 mice. Importantly, exendin 9-39, compound C, and genipin reversed the inhibitory effect of GLP-1R
agonist exendin-4 on Ang II-stimulated mitochondrial ROS rises in SHR endothelial cells. Moreover, exendin-4
improved the endothelial function of renal arteries from SHR and hypertensive patients. Innovation: We
elucidate for the first time that UCP2 serves as an important signal molecule in endothelial protection conferred
by GLP-1-related agents. UCP2 could be a useful target in treating hypertension-related vascular events.
Conclusions: UCP2 inhibits oxidative stress and downregulates COX-2 expression through GLP-1/GLP-1R/
AMPKa cascade. Antioxid. Redox Signal. 21, 1571–1581.
Introduction
Endothelium-dependent contractions (EDCs) asso-ciated with endothelial dysfunction were first observed
in the isolated aortae of spontaneously hypertensive rats
(SHR) (21), and EDCs are correlated with the severity of
hypertension (12). Impaired endothelial function can be ini-
tiated either as a consequence of reduced production/release
of nitric oxide (NO) or by increased inactivation of NO due to
the overproduction of reactive oxygen species (ROS) or the
two factors combined (4). ROS overproduction or increased
oxidative stress has been implicated in the onset and/or
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progression of chronic diseases, including hypertension (2,
24). EDCs are induced by endothelium-derived contracting
factors (EDCFs), including some endothelial cyclooxygenase
(COX)-derived prostanoids or ROS. Constrictive prostanoids
directly activate thromboxane/prostaglandin (TP) endoper-
oxide receptors of the vascular smooth muscle cells (VSMCs)
to induce contraction, whereas ROS stimulate the activity of
COX in endothelial cells or VSMCs to release prostanoids,
such as PGF2a, which stimulate the TP receptors (27, 33, 34).
ROS participate in vascular tone regulation (32), and the
mitochondrion is a major source of ROS (30). The mitochon-
drial uncoupling proteins (UCPs) have emerged as important
natural antioxidants in maintaining cellular ROS homeostasis
(3, 7). UCPs are the inner mitochondrial membrane-associated
proteins, which dissipate the proton electrochemical gradient
formed during mitochondrial respiration and generate heat
production instead of ATP (13). Transcriptional upregulation of
mitochondrial UCP2 abrogates angiotensin II (Ang II)-induced
oxidative stress and alleviates oxidative stress-associated neu-
rogenic hypertension (6). A significant association of hyper-
tension with UCPs, especially UCP2, has been reported in
hypertensive animals and patients (8, 17). UCP2 appears to be a
negative regulator of ROS generation (23, 35). The promoter
polymorphism of the UCP2 gene is associated with hyperten-
sion (17). Furthermore, overexpression of UCP2 inhibits ROS
production in endothelial cells (19).
Our previous study showed that sitagliptin, a highly se-
lective dipeptidyl peptidase-4 (DPP-4) inhibitor, improves
endothelium-dependent relaxations and decreases systolic
blood pressure via elevating NO production in patients and
rats with hypertension (20). The present study aimed to in-
vestigate whether UCP2 contributes to the vascular benefit of
sitagliptin in suppressing EDCs in hypertension.
Results
Sitagliptin attenuated EDCs in SHR renal arteries
EDCs are associated with endothelial dysfunction in hy-
pertension. First, acetylcholine (ACh)-triggered EDCs in
renal arteries from SHR were exaggerated compared to those
from Wistar-Kyoto rats (WKY), and 2-week oral treatment
with sitagliptin markedly attenuated EDCs in arteries from
SHR without affecting those from WKY (Fig. 1A). The
EDCs were likely mediated through COX-2-dependent
mechanism since they were inhibited or abolished by selec-
tive COX-2 inhibitor NS398 (1 lM) and DuP697 (3 lM) or
selective TP receptor antagonists S18886 (0.1lM) but un-
affected by COX-1 inhibitor valeryl salicylate (VAS)
(10 lM) (Fig. 1B). Importantly, chronic sitagliptin treatment
reduced the elevated COX-2 expression in SHR arteries (Fig.
1C). By contrast, COX-1 expression was similar inWKY and
SHR with or without sitagliptin treatment (Supplementary
Fig. S1A; Supplementary Data are available online at
www.liebertpub.com/ars). Furthermore, we have for the first
time demonstrated that the UCP2 expression was signifi-
cantly reduced in SHR renal arteries compared with WKY
controls, and sitagliptin treatment increased the UCP2 ex-
pression in both SHR andWKY arteries (Fig. 1D), suggesting
the possible involvement of UCP2 in contributing to the
vascular benefits of sitagliptin.
Sitagliptin attenuated EDCs via GLP-1R/AMPKa/
UCP2 cascade in SHR renal arteries
To obtain insight into the molecular mechanism of si-
tagliptin to attenuate EDCs, we next explored the effects of
some antagonist or inhibitors on the effects of sitagliptin.
Glucagon-like peptide 1 receptor (GLP-1R) antagonist
exendin 9-39 (100 nM), AMP-activated protein kinase
FIG. 1. Sitagliptin attenuates EDCs in SHR renal ar-
teries. (A) In the presence of l-NAME, ACh elicited pro-
nounced EDCs of renal arterial rings from SHR, which were
inhibited by 2-week administration with sitagliptin. (B) EDCs
in SHR arteries were attenuated or abolished by treatment
with selective COX-2 inhibitor NS398 (1lM) and DuP697
(3lM) or selective TP receptor antagonist S18886 (0.1lM)
but unaffected by COX-1 inhibitor VAS (10lM). COX-2 (C)
and UCP2 (D) expressions in renal arteries from WKY and
SHR. Results are means–SEM of six to eight experiments.
*p< 0.05 versus SHR vehicle, #p< 0.05 versusWKY vehicle.
l-NAME, NG-nitro-l-arginine methyl ester; EDCs, endo-
thelium-dependent contractions; VAS, valeryl salicylate;
ACh, acetylcholine; COX-2, cyclooxygenase-2; TP, throm-
boxane/prostanoid; UCP2, uncoupling protein 2; SHR,
spontaneously hypertensive rats; WKY, Wistar-Kyoto rats.
Innovation
The present study provides novel evidence showing that
cyclooxygenase-2 (COX-2) upregulation mediates endo-
thelium-dependent contractions (EDCs) in arteries from
angiotensin II (Ang II)-infused mice and spontaneously
hypertensive rats (SHR), whereas inhibition of reactive
oxygen species (ROS) production downregulates COX-2
expression and attenuates EDCs in SHR arteries. Un-
coupling protein 2 (UCP2) inhibits mitochondrial ROS
production as an antioxidant protein. The present study
demonstrates that a highly selective dipeptidyl peptidase-
4 inhibitor, sitagliptin, protects endothelial function in
hypertension through elevating the expression of UCP2
and subsequently scavenging mitochondrial ROS, which
in turn downregulates COX-2 expression via the stimu-
lation of the glucagon-like peptide (GLP)-1/GLP-1R/
AMPKa cascade. We have therefore revealed that UCP2
is another effective target for drug intervention to combat
against the hypertension-related vascular diseases.
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(AMPK)a inhibitor compound C (10 lM), and UCP2 inhib-
itor genipin (1lM) augmented the EDCs in renal arteries
from sitagliptin-treated SHR (Fig. 2A) without affecting
those from vehicle-treated SHR (Fig. 2B). Sitagliptin treat-
ment increased AMPK phosphorylation (Fig. 2C) and UCP2
expression (Fig. 2D), whereas it reduced COX-2 expression
(Fig. 2E) in SHR renal arteries. Moreover, the increased
AMPK phosphorylation (Fig. 2C) and elevated UCP2 ex-
pression by sitagliptin were inhibited by exendin 9-39
(100 nM) and compound C (10 lM) but not by genipin (1lM)
(Fig. 2D). On the other hand, the inhibitory effect of si-
tagliptin on COX-2 upregulation was reversed not only by
exendin 9-39 and compound C but also by genipin (Fig. 2E).
These data suggest that UCP2 is likely to mediate the bene-
ficial effect of GLP-1R and AMPK activation to suppress
COX-2 expression in hypertension.
Sitagliptin reduced COX-2 expression via scavenging
mitochondrial ROS in SHR renal arteries
Since the sitagliptin-induced reduction of the COX-2 ex-
pression was due to the upregulation of UCP2, we hypothe-
sized that UCP2 activation decreased the ROS level and
subsequently resulted in COX-2 downregulation. To test this
hypothesis, we investigated the ROS level as well as the
effect of ROS scavengers on EDCs and COX-2 expression in
SHR arteries. First, ROS production increased in renal ar-
teries from SHR compared to those from WKY (Supple-
mentary Fig. S2). Sitagliptin (10mg$kg- 1$day - 1) or in vitro
treatment with tempol (100lM) or tiron (1mM) plus die-
thyldithiocarbamate (DETCA) (100lM) reduced the ROS
level in SHR arteries, whereas exendin 9-39, compound C, or
genipin reversed the inhibitory effects of sitagliptin (Fig. 3A
and Supplementary Fig. S3A, B). Likewise, the results from
lucigenin-enhanced chemiluminescence assay (Fig. 3B) and
electron paramagnetic resonance (EPR) spin trappingmethod
(Fig. 3C and Supplementary Fig. S4) also showed that
sitagliptin-induced reduction of superoxide anion accumu-
lation in SHR arteries was reversed by these inhibitors. Next,
we explored the effects of ROS scavengers on EDCs in SHR
renal arteries and showed that tempol (100lM) or tiron
(1mM) plus DETCA (100lM) reduced EDCs in these ar-
teries (Fig. 3D). Similarly, three mitochondrial ROS scav-
engers, MitoQ (100 nM), coenzyme Q10 (10lM), and
idebenone (10lM), attenuated EDCs (Fig. 3E). Furthermore,
tempol, tiron plus DETCA, coenzyme Q10 (10lM), or ide-
benone (10lM) reduced the expression of COX-2 mRNA
(Fig. 3F) and protein (Fig. 3G) in SHR arteries. Taken to-
gether, the present results suggest that sitagliptin reduces
COX-2 expression most likely through scavenging mito-
chondrial ROS in SHR renal arteries.
Exendin-4 ameliorated endothelial dysfunction in SHR
Our previous study revealed that sitagliptin improved
endothelium-dependent relaxation in a GLP-1-dependent
manner. The present study also confirmed that GLP-1 plays an
important role in the sitagliptin-induced attenuation of EDCs.
Treatment with GLP-1 analog exendin-4 (10 nM, 8 h) dimin-
ished EDCs (Fig. 4A) and the ROS level (Supplementary Fig.
S5) in SHR renal arteries; both effects were reversed by co-
treatment with exendin 9-39 (100nM), compound C (10lM),
or genipin (1lM) (Fig. 4B and Supplementary Fig. S5).
Moreover, both the lucigenin-enhanced chemiluminescence
assay (Fig. 3B) and the EPR method (Fig. 3C) showed that
exendin-4 reduced superoxide anion level in SHR arteries, and
this effect was abolished by genipin. To further demonstrate
that the protective effect of GLP-1 analog is endothelium-
dependent, we tested the action of exendin-4 in primary cultured
SHR endothelial cells (SHRECs). Eight hours of incubation
with exendin-4 (10 nM) reducedmitochondrial ROS production
triggered acutely by Ang II (100nM, 30min) in SHRECs,
which was also inhibited by cotreatment with exendin 9-39,
compound C, or genipin (Fig. 4C, D).
FIG. 2. Sitagliptin attenuates EDCs through the activation of GLP-1 receptor/AMPKa/UCP2 in SHR renal ar-
teries. Effects of GLP-1 receptor antagonist exendin 9-39 (100 nM), AMPKa inhibitor compound C (10lM), and UCP2
inhibitor genipin (1 lM) on EDCs in sitagliptin-treated SHR (A) and vehicle-SHR (B) groups. Level of AMPK phos-
phorylation (C) and expressions of UCP2 (D) and COX-2 (E) in SHR renal arteries. Results are means – SEM of four to
eight experiments. *p < 0.05 versus vehicle, #p < 0.05 versus sitagliptin. Veh, vehicle; C, control; E, exendin 9-39; CC,
compound C; G, genipin; AMPK, AMP-activated protein kinase; GLP-1, glucagon-like peptide 1.
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The critical role of UCP2 in the improvement
of endothelial function by sitagliptin
To explore the critical role of UCP2, we used UCP2
knockout (UCP2KO) mice and adenovirus overexpressing
UCP2. First, we confirmed the beneficial effect of sitagliptin in
Ang II-infused C57BL/6 mice. Ang II infusion unmasked
EDCs in mouse aortae, which were inhibited by cotreatment
with sitagliptin (3mg$kg-1$day- 1) (Fig. 5A).Moreover, acute
treatment with exendin 9-39 (100 nM), compound C (10lM),
or genipin (1lM) enhanced EDCs in aortae from Ang II-
sitagliptin-cotreated mice (Supplementary Fig. S6A) without
affecting those from mice treated with Ang II alone (Supple-
mentary Fig. S6B). Next, we observed that EDCs evoked by
Ang II were unaffected by sitagliptin (3mg$kg- 1$day-1) in
UCP2KO mouse aortae (Fig. 5B). Furthermore, UCP2 over-
expression by adenovirus (AdUCP2) diminished EDCs in SHR
renal arteries (Fig. 5C), further supporting the importance of
UCP2. Western blotting data showed that Ang II reduced
AMPK phosphorylation (Supplementary Fig. S6C), dimin-
ished UCP2 expression (Fig. 5D), and elevated COX-2 ex-
pression (Fig. 5E) in C57BL/6 mouse aortae, which were
reversed by sitagliptin. In addition, exendin 9-39 (100 nM)
and compound C (10lM) but not genipin (1 lM) inhibited the
increased AMPK phosphorylation (Supplementary Fig. S6C)
and elevated UCP2 expression (Fig. 5D) by sitagliptin.
Again, the inhibitory effect of sitagliptin on COX-2 upre-
gulation was reversed by exendin 9–39, compound C, and
genipin (Fig. 5E). We also revealed an elevated COX-2 ex-
pression (Fig. 5F) in UCP2KO mice, which was, however,
unaffected by Ang II or sitagliptin.
Exendin-4 improved endothelial function in renal
arteries from hypertensive patients
To further demonstrate the clinical relevance of the results
from both SHR and Ang II-induced hypertensive mice, we
tested the effect of exendin-4 in human renal arteries. We
FIG. 3. Sitagliptin reduces COX-2 expression via scavenging ROS in SHR renal arteries. Exendin 9-39 (100 nM),
compound C (10lM), or genipin (1lM) reversed the inhibitory effect of sitagliptin (10mg$kg - 1$day - 1) on ROS pro-
duction by DHE staining (A), lucigenin-enhanced chemiluminescence assay (B), and EPR (C). Moreover, acute treatment
with tempol (100 lM) or tiron (1mM) plus DETCA (100lM) (A) reduced ROS level, and genipin (1 lM) also reversed the
ROS-lowering effect of exendin-4 (10 nM) (B, C). ROS scavenger tempol (100lM) or tiron (1mM) plus DETCA (100 lM)
(D) and mitochondrial ROS scavengers MitoQ (100 nM), coenzyme Q10 (10 lM), or idebenone (10lM) (E) reduced or
abolished EDCs in SHR arteries. Tempol (100 lM), tiron (1mM) plus DETCA (100lM), coenzyme Q10 (10 lM), or
idebenone (10lM) reduced COX-2 mRNA (F) and protein expression (G) in SHR arteries. Results are means – SEM of four
to eight experiments. *p < 0.05 versus control, #p < 0.05 versus sitagliptin or exendin-4. Ex9, exendin 9-39; CC, compound
C; G, genipin; ex4, exendin-4; RLU, relative luminance unit; ROS, reactive oxygen species; EPR, electron paramagnetic
resonance; DHE, dihydroethidium; DETCA, diethyldithiocarbamate.
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observed that renal arteries from hypertensive patients ex-
hibited a reduced UCP2 level (Fig. 6A) and an elevated COX-
2 expression (Fig. 6B) compared to those from normotensive
subjects, and such alterations were reversed by ex vivo
treatment with exendin-4. Moreover, exendin-4 treatment
normalized the ROS overproduction in renal arteries from
hypertensive patients (Fig. 6C and Supplementary Fig. S7).
These findings in human renal arteries further support the
vascular benefit of GLP-1 and its analogues to restore the
impaired endothelial function in hypertension.
Discussion
EDCs occur generally in arteries of aged or diseased ani-
mals, including high-fat diet–induced obese mice, SHR, and
diabetic rats and also in young and healthy hamsters (28, 36,
38, 40), which are associated with endothelial dysfunction.
The major findings of the present study include (i) EDCs were
mediated by COX-2-dependent mechanisms in SHR renal
arteries; (ii) in vivo sitagliptin and in vitro exendin-4 treatment
normalized ROS overproduction and attenuated EDCs in SHR
arteries; (iii) sitagliptin treatment upregulated UCP2 expres-
sion and downregulated the elevated expression of COX-2
mRNA and protein through scavenging mitochondrial ROS;
(iv) sitagliptin treatment inhibited EDCs in aortae fromAng II-
infused C57BL/6 mice, and this effect was absent inUCP2KO
mice; (v) UCP2 inhibitor reversed the sitagliptin-induced
beneficial effects in SHR and Ang II-infused mice, whereas
UCP2 overexpression inhibited EDCs in SHR arteries; (vi)
ex vivo exendin-4 treatment reversed endothelial dysfunction
in renal arteries from hypertensive patients.
GLP-1, a 30 amino acid brain–gut insulinotropic peptide,
which is rapidly degraded by DPP-4 in circulation, is now
considered a leading hormone regulating glucose homeo-
stasis in the absorptive state (10, 18). Apart from DPP-4 in-
hibitors (14), more stable GLP-1 analogs have been reported
FIG. 5. The critical role of UCP2 in the improvement of endothelial function by sitagliptin. Ang II unmasked EDCs,
which were inhibited by cotreatment with sitagliptin (3mg$kg - 1$day - 1) in C57BL/6 mice (A) but not in UCP2KO mice
(B). Overexpression of UCP2 by adUCP2 diminished EDC in SHR renal arteries (C). Expressions of UCP2 and COX-2 in
C57BL/6 mice (D, E) and UCP2KO mice (F). Results are means – SEM of five to eight experiments. *p < 0.05 versus
respective control; #p < 0.05 versus Ang II or A, {p < 0.05 versus Ang II + sitagliptin control. C or Ctrl, control; E, exendin 9-
39; CC, compound C; G, genipin; AS, Ang II + sitagliptin; UCP2KO, UCP2 knockout; adUCP2, adenovirus UCP2.
FIG. 4. Exendin-4 ameliorates endothelial dysfunc-
tion in SHR renal arteries. (A) Effects of GLP-1 analog
exendin-4 (10 nM, 8 h) onEDCs in renal arteries fromWKYand
SHR. (B) Effects of exendin 9-39 (100 nM), compound C
(10lM), and genipin (1lM) on exendin-4-induced reduction of
EDCs. (C)Exendin-4 (ex4, 10 nM) reducedmitochondrial ROS
production triggered by Ang II (100 nM) in primary cultured
SHR endothelial cells, which was inhibited by cotreatment with
exendin 9-39 (Ex9, 100 nM), compound C (CC, 10lM), or
genipin (1lM). (D) Images showing mitochondrial ROS pro-
duction under different treatments. Results are means–SEM of
four to six experiments. {p< 0.05versusWKYcontrol, *p< 0.05
versus SHR control, #p<0.05 versus exendin-4. Ang II, angio-
tensin II. To see this illustration in color, the reader is referred to
the web version of this article at www.liebertpub.com/ars
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to exert protective effects in the cardiovascular system (26).
Our previous study also demonstrated that sitagliptin im-
proves endothelium-dependent vasodilatation via restoring
the diminished NO bioavailability in hypertension (20). So
far, the main cause of hypertension-related endothelial dys-
function in humans has been identified with an increased NO
breakdown. In particular, hypertension-related endothelial
dysfunction has been demonstrated to be the consequence of
increased oxidative stress (31). Increased ROS level has a
major impact on vascular tone regulation (9), which is highly
reactive and inactivates NO, thus reducing its bioavailability
and producing peroxynitrites (37). In the present study, we
found that in vivo sitagliptin and in vitro exendin-4 treatment
reduced ROS production based on the following observa-
tions. First, 2-week sitagliptin treatment normalized the
elevated ROS accumulation in SHR renal arteries. Second,
8 h-incubation with exendin-4 reduced the ROS level in SHR
arteries as reflected by the dihydroethidium (DHE) staining,
lucigenin-enhanced chemiluminescence assay, and EPR
method. ROS can serve as the trigger for the release of EDCFs,
which facilitates a greater amplitude of EDCs in hypertensive
rats (33), and this is consistent with the present results that
EDCs in SHR arteries were attenuated by ROS scavengers,
such as tempol, or mitochondrial ROS scavengers, such as
coenzyme Q10 and idebenone. Previous studies showed that
both GLP-1 (16) and sitagliptin (15) suppress ROS production
induced by advanced glycation end products, whereas ex-
endin-4 decreases endogenous ROS production and increases
ATP production in diabetic rat islets (25).
UCP2, a negative regulator of ROS generation (5, 19), has
been detected in a large spectrum of tissues, including endo-
thelial cells (11), and plays an important role in the prevention
of the development of salt sensitivity-related hypertension
(22). The UCP2-dependent action of ghrelin on neurons is
driven by AMPK-related signaling (1), and ghrelin inhibits
insulin secretion in b cells through the AMPK-UCP2 pathway
(39). In addition, AMPK can suppress ROS synthesis via mi-
tochondrial uncoupling mediated through UCP2 (42). Our
previous study showed that GLP-1 signaling leads to AMPK
activation (20). Thus, herewe show that the inhibitory effect of
GLP-1 signaling on EDCs also contributes to endothelial cell
protection in hypertensive animals, which is mediated by
AMPK and UCP2. Furthermore, we confirmed the sitagliptin-
induced elevation of UCP2 expression was mediated through
AMPK activation by using dominant-negative AMPK (DN-
AMPK) adenovirus in SHR renal arteries (Supplementary Fig.
S8). We then verified a critical role of UCP2 in sitagliptin-
induced vascular benefits using both UCP2KO mice and
adUCP2-carried UCP2 overexpression in SHR renal arteries.
Finally, levels of COX-2 expression were assessed in hy-
pertensive animals. The formation of EDCF, which partici-
pates in moment-to-moment regulation in vascular tone,
depends on the activity of endothelial COX (33, 41). Both
COX isoforms, namely COX-1 and COX-2, contribute to the
induction of EDCs (27, 29). The present study shows that
COX-2 expressions increased in renal arteries from SHR and
aortae from Ang II-infused mice compared with respective
control. But COX-1 expression was similar in arteries from
both WKY and SHR and was unaffected by the treatment
with sitagliptin or exendin-4 (Supplementary Fig. S1).
Chronic sitagliptin treatment downregulated COX-2 ex-
pression in arteries from SHR and Ang II-infused mice; this
benefit was reversed by exendin 9-39, compound C, and
genipin. A previous study showed that ROS mediated COX-
2-dependent contraction in renovascular hypertension (34)
and bone morphogenic protein-4 upregulates COX-2 through
ROS (41). Here, we showed that scavengers for ROS and
mitochondrial ROS reduced the raised level of COX-2
mRNA and protein in SHR arteries. In addition, we observed
that H2O2 elevated ROS level and COX-2 expression in
mouse aortic endothelial cells (MAECs), which were unaf-
fected by sitagliptin, but only inhibited by catalase (Supple-
mentary Fig. S3C–E).We further evaluated the COX-2 levels
in the vascular wall of mouse aortae. In consistence with
western blotting results on intact aortae, the immunohisto-
chemical staining also showed a significantly higher basal
COX-2 expression in VSMCs of aortae from UCP2KO mice
compared to C57BL/6 mice (Supplementary Fig. S9A),
suggesting that UCP2 might be a physiological inhibitor of
the COX-2 expression in aortic vascular wall of healthy mice.
Two-week Ang II infusion significantly elevated the COX-2
expression in C57BL/6mouse aortic VSMCswith little effect
in UCP2KO mouse aortic VSMCs. Chronic sitagliptin
treatment downregulated the COX-2 expression in aortic
VSMCs from C57BL/6 mice but only induced a small de-
crease in the COX-2 expression of aortic VSMCs from
UCP2KO mice. Although the en face immunofluorescence
staining showed that the basal COX-2 expression was com-
parable, but it was elevated by Ang II treatment to a similar
degree in aortic endothelium from both C57BL/6 mice and
UCP2KO mice (Supplementary Fig. S9B). These results
suggest that endothelial cell COX-2 upregulation is likely the
primary mediator of EDCs in Ang II-treated aortae from both
C57BL/6 and UCP2KO mice, and this also explains the ob-
servation that sitagliptin treatment reduces the COX-2 ex-
pression in the endothelium and inhibits EDCs in aortae from
Ang II-infused C57BL/6 mice without affecting both alter-
ations in Ang II-infused UCP2KO mouse aortae. Taken to-
gether, the present results indicate that sitagliptin and
exendin-4 attenuate EDCs by reducing COX-2 expression via
UCP2 upregulation and subsequent inhibition of mitochon-
drial ROS production. Of importance, the present study also
FIG. 6. Exendin-4 improves endothelial
function in renal arteries from HT. UCP2 (A)
and COX-2 (B) expressions in human renal
arteries. (C) DHE fluorescence of ROS in hu-
man renal arteries. Results are means – SEM of
four experiments. *p< 0.05 versus NT;
#p < 0.05 versus HT. C, control; E, exendin-4;
NT, normotensive patients; HT, hypertensive
patients.
1576 LIU ET AL.
shows the reduced UCP2 level, elevated COX-2 expression,
and increased ROS level in renal arteries from patients with
hypertension, and such changes were normalized by ex vivo
treatment with exendin-4.
In conclusion, EDCs visualized in arteries from Ang II-
infused mice and SHR are COX-2-dependent. Sitagliptin
treatment attenuates EDCs through normalizing COX-2
overexpression via the activation of GLP-1R/AMPKa/UCP2
signaling cascade (Fig. 7). Based on the therapeutic profile of
sitagliptin to prevent hypertension, the orally active and
stable GLP-1 analogs might be useful for the treatment of
vascular dysfunction in hypertension-related vascular events.
Materials and Methods
Chemicals
Anti-phospho-AMPKa (Thr172) and anti-AMPKa were
purchased from Cell Signaling Technology (Beverly, MA).
Anti-COX-2 antibody was obtained from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). Anti-UCP2 antibody was
purchased fromR&D Systems (Minneapolis, MN). Antibody
against GAPDH was obtained from Ambion (Austin, TX).
HRP-conjugated swine anti-goat, anti-rabbit, or anti-mouse
IgG were from DakoCytomation (Carpinteria, CA). Im-
mobilon-P polyvinylidene difluoride (PVDF) membrane was
from Millipore (Billerica, MA), and chemiluminescence
(ECL reagents) was obtained from Amersham Pharmacia
(GE Healthcare Life Sciences, Buckinghamshire, United
Kingdom). ACh,NG-nitro-l-argininemethyl ester (l-NAME),
compound C, exendin-4, exendin 9-39, DuP697, tempol, tiron,
DETCA, bis-N-methylacridinium nitrate (lucigenin), and b-
nicotinamide adenine dinucleotide phosphate (NADPH) were
purchased from Sigma-Aldrich Chemical (St Louis, MO).
VAS and genipin were from Cayman Chemical (Ann Arbor,
MI). Ang II, coenzyme Q10, idebenone, and NS398 were from
Tocris Bioscience (Bristol, United Kingdom).MitoQwas from
Antipodean Pharmaceuticals. S18886 was a gift from the
Institut de Recherches Servier (Suresnes, France). 1-Hydroxy-
2,2,6,6-tetramethyl-4-oxo-piperidine hydrochloride (TEM-
PONE-H) was from Alexis Biochemical Corp. (San Diego,
CA). The cell culture media, DHE, andMitoSOXwere from
Invitrogen (Carlsbad, CA). Sitagliptin was a kind gift from
Merck Research Laboratories (Rahway, NJ). DHE, MitoSOX,
DuP697, NS398, idebenone, VAS, S18886, genipin, and
compound C were dissolved in DMSO. Coenzyme Q10 and
MitoQ were dissolved in ethanol. Other drugs were dissolved
in distilled water. DMSO and ethanol (0.1% v/v) did not
modify ACh-induced contraction.
Animals
Male SHR,WKY, and C57BL/6 mice were supplied by the
Chinese University of Hong Kong (CUHK) Laboratory An-
imal Service Center. Male UCP2KO mice of C57BL/6
background were purchased from the Jackson Laboratory
(Bar Harbor, ME) and maintained in the University of Hong
Kong. This investigation was approved by the CUHKAnimal
Experimentation Ethics Committee and conformed to the
Guide for the Care and Use of Laboratory Animals published
by the US National Institute of Health (NIH Publication No.
85-23, revised 1996). SHR (32–40 weeks old) andWKY (32–
40 weeks old) received sitagliptin (10mg$kg- 1$day - 1 by
oral gavage) or vehicle for 2 weeks. Ang II- or PBS-loaded
osmotic pumps were implanted under ketamine/xylazine
anesthesia (75 and 6mg$kg - 1 body weight) in C57BL/6 and
UCP2KO mice (8–10 weeks) and received sitagliptin ad-
ministration (3mg$kg - 1$day - 1) or vehicle for 2 weeks.
Human artery specimen
The present study was approved by the Joint Chinese Uni-
versity of Hong Kong-New Territories East Cluster Clinical
Research Ethics Committee. Human renal arteries were ob-
tained after informed consent from normotensive and hyper-
tensive patients undergoing nephrectomy at ages between 50
and 80 years. The indications for surgery included tumor (three
in normotensive patients and two in hypertensive patients) and
poorly functioning kidney (one in normotensive patients and
two in hypertensive patients). History of hypertension was
defined as having persistent elevated blood pressure, systolic
blood pressure of > 140mm Hg, or diastolic blood pressure
of > 90mm Hg and requiring medical therapy.
Isometric force measurement
Rats and mice were sacrificed by CO2 suffocation. Renal
arteries from rats and aortae from mice were removed and
placed in ice-cold Krebs solution (mM): 119 NaCl, 4.7KCl,
2.5 CaCl2, 1MgCl2, 25NaHCO3, 1.2KH2PO4, and 11 d-
glucose. Arteries were cleaned of adhering tissue and cut into
FIG. 7. The proposed cellular mechanism for the pro-
tective effect of sitagliptin against endothelial dysfunc-
tion in hypertension. Ang II evoked EDCs by increasing
ROS level/COX-2 expression. Sitagliptin elevates UCP2
expression via the activation of GLP-1 receptor/AMPKa
through GLP-1-dependent pathway, leading to reduced ROS
production and subsequent downregulation of COX-2 ex-
pression, thus attenuates EDCs in hypertension.
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ring segments of 2mm in length. Rings were suspended in
myograph (Danish Myo Technology, Aarhus, Denmark) for
recording of changes in isometric tension (41). Briefly, to vi-
sualize the EDCs, rings with endothelium were exposed to
100lM l-NAME for 30min to eliminate the relaxant effect of
endothelium-derived NO before the application of ACh (0.01
to 100lM). The effects of various inhibitors and antagonists
(e.g., UCP2 inhibitor, COX-2 inhibitors, or TP receptor an-
tagonist) were tested on ACh-induced contractions following
30-min incubation with each drug. In some experiments, SHR
renal arteries were incubated with ROS scavengers or exendin
9-39 (100nM, GLP-1R antagonist), compound C (10lM,
AMPKa inhibitor), and genipin (1lM, UCP2 inhibitor) along
with exendin-4 (10 nM, GLP-1 analog) for 8 h.
Primary culture of rat aortic endothelial cells
Aortae of SHR were dissected in sterilized phosphate-
buffered saline (PBS) under a stereoscopic microscope. After
digestion by 0.2% collagenase for 15min at 37C, RPMI-
1640 was added, and endothelial cells were then collected by
centrifugation at 1000 rpm for 5min. Thereafter, the pellet
was gently re-suspended in RPMI-1640 supplemented with
10% FBS and cultured in a 75-mm culture flask. To remove
other cell types, the medium was changed after 1-h incuba-
tion and then maintained until 70% confluence before use.
Primary culture of MAECs
Mice were anesthetized with an intraperitoneal injection of
ketamine/xylazine. Heparin (100U/ml in PBS) was infused
into the circulation from the left ventricle. The aortae were
dissected in DMEM and incubated with collagenase type II
for 8min at 37C. Detached endothelial cells were collected
by centrifugation, resuspended in 20% FBS-DMEM and then
cultured in endothelial cell growth medium supplemented
with bovine brain extract (Lonza, Walkersville, MD) till
confluency before use (35). The identity of endothelial cells
was confirmed by immunocytochemical staining for an en-
dothelial cell-specific maker, PECAM-1.
Western blot analysis
Isolated renal arteries, mouse aortae, or MAEC were ho-
mogenized in RIPA lysis buffer that contained 1 lg/ml leu-
peptin, 5 lg/ml aprotinin, 100lg/ml PMSF, 1mM sodium
orthovanadate, 1mM EDTA, 1mM EGTA, 1mM sodium
fluoride, and 2lg/ml b-glycerolphosphate, and centrifuged at
20,000 g for 20min at 4C. Protein lysates (25lg for arteries,
10 lg for cells) were separated by electrophoresis and
transferred onto immobilon-P PVDF membrane. Blots were
blocked with 1% bovine serum albumin or 5% nonfat milk
for 1 h and incubated overnight at 4Cwith antibodies against
phosphorylated AMPKa, total AMPKa, UCP2, COX-2, and
GAPDH. After washing, blots were incubated with HRP-
conjugated swine anti-rabbit, anti-mouse, or anti-goat IgG
(DakoCytomation, Carpinteria, CA). Immunoreactive bands
were visualized by chemiluminescence (ECL reagents,
Amersham Pharmacia) and exposed to Kodak Image Station
440 for densitometric analysis.
Real-time polymerase chain reaction
The effect of ROS scavengers on COX-2 transcription was
examined by real-time polymerase chain reaction (PCR).
Total RNA from rat renal arteries was extracted using the
Aurum total RNA Mini kit (BioRad, Hercules, CA) accord-
ing to the manufacturers’ instructions and then reverse tran-
scribed using the iScriptTMcDNA synthesis kit (Bio-Rad
Laboratories, Hercules, CA). Real-time PCR was performed
with SYBRPremix Ex TaqTM (Invitrogen) with thermal
cycles at 95C for 5min, 40 cycles at 95C for 1min, 1min Tm
(melting temperature), 72C for 1min, finally followed at
72C for 5min with the specific primer sets. The forward
primer for COX-2: 5¢-GCAAATCCTTGCTGTTCCAATC-
3¢, the reverse primer for COX-2: 5¢-GGAGAAGGCTTCCC
AGCTTTTG-3¢. The forward primer for GAPDH: 5¢-TGCAC
CACCAACTGCTTAGC-3¢, the reverse primer for GAPDH:
5¢-CAGTCTTCTGAGTGGCAGTGATG-3¢. PCR conditions
were as follows: 1 cycle at 95C for 3min, followed by 45
cycles at 95C for 20 s, 63C for 20 s, and 72C for 20 s. COX-
2 mRNA levels were normalized by GAPDH.
DHE staining
Frozen sections or MAEC seeded on glass coverslips were
loaded with 5lMDHE at 37C for 10min. ROS fluorescence
was measured by a confocal scanning unit (Olympus, Tokyo,
Japan) at excitation 515 nm and emission 585 nm. Data were
analyzed by the Fluoview software (Olympus).
Detection of superoxide anions
The formation of superoxide anions in arteries was measured
using the lucigenin-enhanced chemiluminescence method (43).
Briefly, isolated SHR renal arteries was preincubated for 45min
at 37C in 2ml of Krebs–HEPES buffer (in mM: NaCl 99.0,
NaHCO3 25.0, KCl 4.7, KH2PO4 1.0, MgSO4$7H2O 1.2, glu-
cose 11.0, CaCl2$2H2O 2.5, and Na-HEPES 20.0) in the pres-
ence of DETCA (1mM) to inactivate superoxide dismutase and
b-NADPH (NADPH oxidase substrate, 0.1mM). The arteries
were then transferred to vials containing 300ll Krebs–HEPES
buffer with 10lM lucigenin, and the repeated measurement
were taken over 10min in 1-min intervals using the lumin-
ometer (GloMax 20/20Luminometer,Madison,WI). The data
were expressed as average counts per mg of tissue dry weight.
ROS detection by EPR spin trapping
ROS levels in SHR renal arteries were also determined
by EPR using 1-hydroxy-1-hydroxy-2,2,6,6-tetramethyl-4-
oxo-piperidine hydrochloride (TEMPONE-H; Alexis Bio-
chemical Corp., SanDiego, CA) as the spin trapping agent (40).
Mitochondrial ROS measurement
SHR aortic endothelial cells seeded on glass coverslips
were incubated with exendin-4 (10 nM, 8 h) in the presence or
absence of various inhibitors and then placed in a chamber
designed for fluorescence imaging. Mitochondrial ROS
production triggered by Ang II (100 nM) was monitored us-
ing a fluorescent ROS indicator MitoSOX (5lM). ROS
fluorescence was measured by a confocal scanning unit
(FV1000; Olympus) at excitation of 515 nm and emission of
585 nm. Data were expressed as percentage change before
(F0) and after (F1) the addition of Ang II.
Statistical analysis
EDCs were expressed as the percentage of 60mM KCl-
induced tension. Results are means – SEM of n rings from
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different animals. For statistical analysis, the Student’s t-test
or two-way ANOVA, followed by Bonferroni post hoc tests
were used when more than two treatments were compared
(GraphPad Software, San Diego, CA). p< 0.05 was consid-
ered significantly different.
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Abbreviations Used
ACh¼ acetylcholine
adUCP2¼ adenovirus UCP2
AMPK¼AMP-activated protein kinase
Ang II¼ angiotensin II
COX-2¼ cyclooxygenase-2
DETCA¼ diethyldithiocarbamate
DHE¼ dihydroethidium
DN-AMPK¼ dominant-negative AMPK
DPP-4¼ dipeptidyl peptidase-4
EDC¼ endothelium-dependent contraction
EDCFs¼ endothelium-derived contracting factors
EPR¼ electron paramagnetic resonance
GLP-1R¼ glucagon-like peptide 1 receptor
HT¼ hypertensive patients
l-NAME¼NG-nitro-l-arginine methyl ester
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MAECs¼mouse aortic endothelial cells
NADPH¼ nicotinamide adenine dinucleotide
phosphate
NO¼ nitric oxide
NT¼ normotensive patients
PBS¼ phosphate-buffered saline
PCR¼ polymerase chain reaction
PVDF¼ polyvinylidene difluoride
RLU¼ relative luminance unit
ROS¼ reactive oxygen species
TP¼ thromboxane/prostanoid
UCP2¼ uncoupling protein 2
UCP2KO¼UCP2 knockout
SHR¼ spontaneously hypertensive rat
SHREC¼ SHR endothelial cell
VAS¼ valeryl salicylate
VE-cadherin¼ vascular endothelial cadherin
VSMC¼ vascular smooth muscle cell
WKY¼Wistar-Kyoto rats
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